Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SomaLogic Announces the Launch of SomaSciences in the UK at ELRIG ‘Companion Diagnostics’ Conference

Published: Monday, March 19, 2012
Last Updated: Monday, March 19, 2012
Bookmark and Share
Proteomic technology now available to pharmaceutical companies and academic research groups looking to discover and validate protein biomarkers for diverse applications.

SomaLogic, Inc., has announced the launch of SomaSciences in the United Kingdom, making SomaLogic’s proteomic technology available to researchers across the country who seek to improve and accelerate their protein biomarker discovery efforts.

The SomaSciences launch will take place at the ELRIG - ‘Companion Diagnostics’ Conference on May 1, 2012 at The Belfry, Oxford.

Steven Williams, M.D., Ph.D., Chief Medical Officer of SomaLogic, will present the company’s technology in a talk entitled
“Unlocking protein biomarker discovery for diagnostics and therapeutics; Rapid translation to diagnostic products”.

“We are delighted that this is the first formal European availability of our technology,” said Dr. Williams. “We look forward to building on our current strong collaborations in the UK and establishing new ones that will create additional opportunities for building transformative health care products.”

Proteins provide the most immediate, real-time measure of the state of health and disease in individual patients.

However, the ability to accurately identify and measure the thousands of proteins present in small amounts of biological sample in a high-throughput and wide-ranging manner has proven technologically unfeasible.

SomaLogic’s proprietary SOMAscan™ proteomic assay overcomes many of the limitations of current technologies, and provides a “one stop shop” for the entire process from basic biomarker discovery to validated companion diagnostic.

The SOMAscan technology also provides unprecedented protein biomarker support for drug discovery and development, including target discovery and validation, mechanism of action, prediction of efficacy, patient stratification, and drug response monitoring.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SomaLogic Raises Up to $60.5 Million From Visium Healthcare Partners
Company has announced that it has received up to $60.5 million through a combination of debt and equity financing from Visium to support strategic growth initiatives.
Tuesday, March 08, 2016
SomaLogic Raises up to $60.5M
SomaLogic, Inc., and Visium Healthcare Partners, LP has announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium.
Wednesday, March 02, 2016
NEC and SomaLogic Enter Agreement to Prepare for Delivery of Novel Forms of Health Information via Cloud Services
Partnership seeks to accelerate worldwide clinical use of SomaLogic’s aptamer-based diagnostic technology.
Tuesday, August 31, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!